Neuphoria Therapeutics Inc. NEUP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -92.50% | -100.08% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.50% | -100.08% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -92.50% | -100.08% | -- | -- | -- |
| SG&A Expenses | -4.14% | -4.13% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.20% | -9.20% | -- | -- | -- |
| Operating Income | -986.67% | -3,015.55% | -- | -- | -- |
| Income Before Tax | -1,521.85% | -418.40% | -- | -- | -- |
| Income Tax Expenses | 70.28% | -57.27% | -- | -- | -- |
| Earnings from Continuing Operations | -3,539.61% | -399.14% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,539.61% | -399.14% | -- | -- | -- |
| EBIT | -986.67% | -3,015.55% | -- | -- | -- |
| EBITDA | -4,919.00% | -7,383.51% | -- | -- | -- |
| EPS Basic | -18,967.92% | -750.91% | -- | -- | -- |
| Normalized Basic EPS | -980.78% | -451.83% | -- | -- | -- |
| EPS Diluted | -1,060.35% | -1,364.89% | -- | -- | -- |
| Normalized Diluted EPS | -980.78% | -451.83% | -- | -- | -- |
| Average Basic Shares Outstanding | 170.96% | 161.21% | -- | -- | -- |
| Average Diluted Shares Outstanding | 170.96% | 161.21% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |